An Evaluation of the CPI Indexes for Prescription Drugs

Barry Bosworth, John Bieler, Michael Kleinrock, Eric Koepcke and Ernst R. Berndt

No 24210, NBER Working Papers from National Bureau of Economic Research, Inc

Abstract: The prescription drug component of the Consumer Price Index (CPI measures recent and past drug price changes, and provides the basis for projecting future price trends and health care expenditures. However, there are concerns about the adequacy of the price data because of recent changes in the structure of the market for prescription drugs. We compare the prescription drug data of the CPI with a large alternative data set from the IQVIA Institute for Human Data Science. We analyze the overall consistency if the data from the two sources, and examine the influence of the large shift from brand to generic drug sales and the increased reliance on third party insurance plans that are excluded from the CPI sampling frame.

JEL-codes: D04 I11 I18 L11 L65 (search for similar items in EconPapers)
Date: 2018-01
New Economics Papers: this item is included in nep-hea and nep-mkt
Note: EH IO PR
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://www.nber.org/papers/w24210.pdf (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nbr:nberwo:24210

Ordering information: This working paper can be ordered from
http://www.nber.org/papers/w24210

Access Statistics for this paper

More papers in NBER Working Papers from National Bureau of Economic Research, Inc National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.. Contact information at EDIRC.
Bibliographic data for series maintained by ().